Core Insights - Eisai Co., Ltd. will present clinical data on the selective orexin 2 receptor agonist E2086 and the orexin receptor antagonist lemborexant (DAYVIGO®) at the World Sleep Congress in Singapore from September 5 to 10, 2025 [1][2] Group 1: Presentations and Studies - Key presentations include results from the Phase Ib clinical study of E2086 for narcolepsy type 1 and the Phase IV SELENADE Study on lemborexant's effects in patients with insomnia and depressive episodes [2] - The company will host a symposium to introduce the latest evidence on lemborexant in Asia [2] Group 2: Focus Areas - Eisai focuses on neurology, particularly sleep disorders like insomnia and narcolepsy, aiming to create innovative products for high unmet medical needs [3] - The company seeks to enhance the quality of life for individuals with neurological diseases and their families [3] Group 3: Presentation Schedule - Oral presentations will include E2086's effects on wakefulness in narcolepsy type 1 on September 8 [4] - Multiple poster presentations on lemborexant will cover various studies, including its safety and efficacy in different populations and conditions [4][5] Group 4: Product Information - Lemborexant (DAYVIGO) is an orexin receptor antagonist approved in over 25 countries, designed to improve sleep onset and maintenance with minimal residual effects [7] - E2086 is a novel selective orexin 2 receptor agonist that has shown potential in increasing wakefulness and reducing cataplexy in nonclinical studies [8]